LearnOn Podcast: The Science Show By Kids, For Everyone!

Throughout this season in the podcast, we have explored the unique role of cutting-edge technology in driving innovation for medicine. But what about the other way around? It turns out that the unique makeup of the healthcare system is crucial in the context of leading changes in digital health. Today, we're hearing from Noelle Eder, CIO at The Cigna Group, for her insights through a career of over 30 years. Tune in to hear about the verticalization of American healthcare, how the fragmentation of this space affects the demand for innovation in medical technology, and the importance of empathy in leadership. Noelle Eder is the Executive Vice President and Global Chief Information Officer (CIO) at The Cigna Group. Prior to this role, she served as the Chief Information and Digital Officer at Hilton Worldwide Holdings, the Chief Card Customer Experience Officer for Capital One Financial Corporation, as well as other technology leadership roles at Intuit and TeKnowledge.

As technology gets better than ever, we're unlocking new medical discoveries with the potential to earn billions. However, it's important to not lose sight of what drove us towards these discoveries in the first place: the needs of the patients, and in the case of diseases such as Alzheimer's, their caregivers. Today, we're joined by Dr. Brandy Matthews on behalf of Eli Lilly, which is currently the largest pharmaceutical company in the world with a market cap of over $800 billion. Join us as Dr. Matthews talks us through the recent FDA approval of Alzheimer's drug Kisunla, learning from negative trials, and adopting a treatment approach centering patients and caregivers through the LillyDirect program. See more of Lilly's work: www.lilly.com/ [https://www.lilly.com/] Dr. Brandy Matthews is the Vice President of Global and US Medical Affairs for Alzheimer's disease at Eli Lilly and Company. She has a background in clinical neurology with a medical degree from the Indiana University School of Medicine and a completed neurology residency at the Mayo Clinic.

It's always exciting to see flashy headlines about the next revolutionary drug approved by the FDA or how a biotech startup is making millions for a diagnostic test. However, it's equally important to not lose sight of what gets us to the most important discoveries in the first place: basic research. Today, we're interviewing Dr. Marc Kirschner, a renowned cell biologist and biochemist known for his research on the cytoskeleton, cell cycle, and embryo signaling. Join us to hear his thoughts on how scientific disciplines have become more intertwined over time, the crucial role of technological advancements such as electron microscopy in the field of biochemistry, and the dire need for approaching scientific discovery with curiosity instead of going straight for the money. Dr. Marc Kirschner is the founding chair of the Department of Systems Biology at Harvard Medical School and is known for major discoveries in cell and developmental biology. He has also coauthored 2 books on the biological basis of evolution and helped launch the peer-reviewed journal PLOS (Public Library of Science) Biology.

It's always interesting to think about how many technologies that we take for granted today, such as genome sequencing and bioengineering, were completely unheard of just a few decades ago. This episode, we're going back to the roots of these applications with Dr. James Collins, who is widely regarded as one of the founders of the field of synthetic biology. Tune in to hear his thoughts on the importance of leveraging the tools we have today for pandemic prevention and readiness, how to reframe thinking around biosecurity when it comes to applications of these technologies, and how AI can help us outrun antibiotic resistance with rapid drug discovery. Dr. James Collins is a professor of medical engineering and science at MIT, a core faculty member at the Wyss Institute of Harvard University, and a member of the Broad Institute of MIT and Harvard. He is a member of the National Academies of Engineering, Science, and Medicine, and his technologies have been licensed by over 25 biotech and medical device companies.

You've probably heard about gene editing to create hybrid species or designer babies. But what about its purpose to aid the wellbeing of humanity? Today, we're joined by Ian Karp on behalf of Intellia Therapeutics, a biotechnology company employing CRISPR-based gene editing to develop curative therapeutics for cancer and autoimmune disease. Tune in to hear his thoughts on recent clinical trial updates, how to effectively communicate the purpose of these therapies with the public, and what it's like to be at the forefront of medical innovation when it comes to gene editing. Check out the work that Intellia is doing: www.intelliatx.com/ [https://www.intelliatx.com/] Ian Karp is a Senior Vice President at Intellia Therapeutics. He has over 25 years of expertise in the biopharmaceutical industry for investor relations, corporate communications, business development, and product commercialization.